Our pipeline

Open to licensing

Field
Target

Discovery

Lead Gen

Lead Opt

Pre-clinical

Clinical

Dengue virus

NS4B

Title

90%

Phase II

Respiratory syncytial virus

RNA polymerase

Title

60%

Pre-clinical

Peripheral inflammation

cGAS

Title

60%

Lead Optimisation

Neuro-inflammation

cGAS

Title

60%

Lead Optimisation

HDV/HBV - PSC/PBC

NTCP

Title

60%

Lead Optimisation

Nontuberculous mycobacteria

RNA polymerase

Title

55%

Lead Optimisation

SARS - COVID-19

Membrane Protein

Title

48%

Lead Optimisation

Enterovirus

3Cpro

Title

40%

Lead Optimisation

ADPKD

Not Disclosed

Title

35%

Hit to lead

Parkinson's Disease

Alphasynuclein

Title

29%

Hit to lead

Pancreatic cancer

Hippo pathway

Title

28%

Hit to lead

Henipavirus

Multiple

Title

22%

Hit to lead

Pan/Epidemic Viruses

Multiple

Title

20%

Hit to lead

Hypertrophic Cardiomyopathy

Not Disclosed

Title

10%

Hit ID

Advanced partnered projects

Undisclosed

Field: CNS
Target: ATP13A2/10B

Field: Immune Oncology
Target: PTPN2

Drug Screening Services

Discovery/Pre-clinical

Field: Cancer
Target: Undisclosed

Field: MS
Target: GPR17

Field: Liver Fibrosis
Target: Stellate cells

Phase I

Field: Cancer
Target: YAP/TEAD

Phase II

Field: pain
Target: TRPM3

Field: SARS-CoV-2
Target: MPro

Business deals

CD3 announces investment in Enedra Therapeutics to advance drug discovery programmes from its proprietary CASPAROV platform for difficult to treat cancers
CD3 announces investment in Enedra Therapeutics to advance drug discovery programmes from its proprietary CASPAROV platform for difficult to treat cancers

CD3 announces investment in Enedra Therapeutics to advance drug discovery programmes from its proprietary CASPAROV platform for difficult to treat cancers

Enedra Therapeutics, a London-based drug discovery and development company, has secured venture financing and non-dilutive funding through UKRI’s Innovate UK Future Economy Investor Partnerships programme…
May 6, 2025
KU Leuven joins EndLyz Therapeutics’ fight against Parkinson’s disease
KU Leuven joins EndLyz Therapeutics’ fight against Parkinson’s disease

KU Leuven joins EndLyz Therapeutics’ fight against Parkinson’s disease

EndLyz Therapeutics, a UK-based biotech company, announces a collaboration with KU Leuven professor Peter Vangheluwe and the Center for Drug Design and Discovery (CD3). Together…
April 10, 2025
CD3 and the KULeuven Lab of Cellular Transport Systems Join Forces with SandboxAQ to Speed Identification of New Therapies for the treatment of Parkinson’s Disease
CD3 and the KULeuven Lab of Cellular Transport Systems Join Forces with SandboxAQ to Speed Identification of New Therapies for the treatment of Parkinson’s Disease

CD3 and the KULeuven Lab of Cellular Transport Systems Join Forces with SandboxAQ to Speed Identification of New Therapies for the treatment of Parkinson’s Disease

With the support of The Michael J. Fox Foundation for Parkinson’s Research (MJFF), CD3 and the Lab of Cellular Transport Systems (LCTS), led by Prof.…
November 29, 2024
Janssen Announces Promising Antiviral Activity Against Dengue in a Phase 2a Human Challenge Model
Janssen Announces Promising Antiviral Activity Against Dengue in a Phase 2a Human Challenge Model

Janssen Announces Promising Antiviral Activity Against Dengue in a Phase 2a Human Challenge Model

Janssen shared Phase 2a data of our Dengue antiviral. Good news: JNJ-1802 induced antiviral activity against dengue virus in humans!   More information can be…
October 26, 2023
KU Leuven announces collaboration and license agreement with Gilead Sciences for the development of new antivirals against the respiratory syncytial virus
KU Leuven announces collaboration and license agreement with Gilead Sciences for the development of new antivirals against the respiratory syncytial virus

KU Leuven announces collaboration and license agreement with Gilead Sciences for the development of new antivirals against the respiratory syncytial virus

KU Leuven’s Rega Institute for Medical Research and the Centre for Drug Design and Discovery (CD3) today announced that they recently entered into a collaboration…
May 17, 2022
Biohaven Enters Exclusive License and Research Collaboration Agreement with KU Leuven to Advance First-in-Class TRPM3 Antagonists for the Treatment of Pain
Biohaven Enters Exclusive License and Research Collaboration Agreement with KU Leuven to Advance First-in-Class TRPM3 Antagonists for the Treatment of Pain

Biohaven Enters Exclusive License and Research Collaboration Agreement with KU Leuven to Advance First-in-Class TRPM3 Antagonists for the Treatment of Pain

Biohaven Therapeutics Ltd., a subsidiary of Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), along with CD3 and LICR at KU Leuven, announced today that they…
January 10, 2022
KU Leuven develops very potent antiviral against dengue
KU Leuven develops very potent antiviral against dengue

KU Leuven develops very potent antiviral against dengue

Researchers at the KU Leuven Rega Institute and CD3 have developed an ultrapotent inhibitor of the dengue virus, which causes the tropical disease known as…
October 6, 2021
CD3 and VIB Enter into an Exclusive License and Research Collaboration with SpringWorks Therapeutics to Develop TEAD Inhibitors for Addressing Biomarker-Defined Cancers
CD3 and VIB Enter into an Exclusive License and Research Collaboration with SpringWorks Therapeutics to Develop TEAD Inhibitors for Addressing Biomarker-Defined Cancers

CD3 and VIB Enter into an Exclusive License and Research Collaboration with SpringWorks Therapeutics to Develop TEAD Inhibitors for Addressing Biomarker-Defined Cancers

TEAD inhibition holds great promise as a therapeutic approach as the Hippo pathway is genetically altered in up to 10% of cancers. In mesothelioma, an…
May 6, 2021
Aligos and KU Leuven collaborate to develop a therapeutic candidate targeting coronavirus
Aligos and KU Leuven collaborate to develop a therapeutic candidate targeting coronavirus

Aligos and KU Leuven collaborate to develop a therapeutic candidate targeting coronavirus

Aligos Therapeutics, Inc. (Aligos), a private biotechnology company focused on the development of targeted antiviral therapies directed against chronic hepatitis B (CHB), COVID-19 and therapeutics…
July 2, 2020
Cytura Therapeutics to Develop a New Class of Drugs Targeting Genomic Instability in Cancer
Cytura Therapeutics to Develop a New Class of Drugs Targeting Genomic Instability in Cancer

Cytura Therapeutics to Develop a New Class of Drugs Targeting Genomic Instability in Cancer

Cytura Therapeutics announced the successful closure of a seed financing round. The funding is provided by a syndicate led by Thuja Capital Healthcare (Seed) Fund…
April 23, 2019
CD3, VIB and Beactica announce drug discovery alliance targeting inflammatory diseases
CD3, VIB and Beactica announce drug discovery alliance targeting inflammatory diseases

CD3, VIB and Beactica announce drug discovery alliance targeting inflammatory diseases

KU Leuven’s Centre for Drug Design and Discovery (CD3), VIB and Beactica AB, the Swedish drug discovery company, are proud to announce a new partnership.…
February 28, 2019
Grünenthal and KU Leuven join forces to develop an innovative non-opioid pain treatment
Grünenthal and KU Leuven join forces to develop an innovative non-opioid pain treatment

Grünenthal and KU Leuven join forces to develop an innovative non-opioid pain treatment

Grünenthal, KU Leuven’s Centre for Drug Design and Discovery (CD3) and the Laboratory of Ion Channel Research (LICR) announced today that they have entered into…
April 12, 2018
VIB, CD3 and Galapagos NV enter into a license deal for the development of MALT1 inhibitors
VIB, CD3 and Galapagos NV enter into a license deal for the development of MALT1 inhibitors

VIB, CD3 and Galapagos NV enter into a license deal for the development of MALT1 inhibitors

VIB, the Centre for Drug Design and Discovery of KU Leuven (CD3) and Galapagos NV signed an exclusive license and collaboration agreement for the development…
January 10, 2018
Rewind Therapeutics secures 15.2 million euro to develop novel remyelination therapies for MS
Rewind Therapeutics secures 15.2 million euro to develop novel remyelination therapies for MS

Rewind Therapeutics secures 15.2 million euro to develop novel remyelination therapies for MS

Rewind Therapeutics completed a €15.2 million Series A financing to develop novel re-myelinating therapies for patients suffering from Multiple Sclerosis (MS) and other myelin-related diseases.…
January 4, 2018
Hit Discovery Constance GmbH: a new European hub for HTS and compound management
Hit Discovery Constance GmbH: a new European hub for HTS and compound management

Hit Discovery Constance GmbH: a new European hub for HTS and compound management

Constance (Germany), January 14th, 2014 – Today Hit Discovery Constance GmbH (HDC), a new joint venture organisation between Lead Discovery Center (Dortmund/Germany), Centre for Drug…
January 14, 2014